BCAX — Bicara Therapeutics Inc. Common Stock stock price, charts and financials

QT88Bicara Therapeutics Inc. Common Stock

Bicara Therapeutics Inc. Common Stock (NASDAQ: BCAX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
25.74
-1.36-5.02%
OverviewShort InterestFilings
BCAXQT88Bicara Therapeutics Inc. Common Stock·NASDAQ
25.74-5.02%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
IOVA+6.14%$4.32FTRE-1.20%$18.94SLS+12.09%$11.22URGN+0.92%$38.59MESO+2.12%$14.47TSHA-1.37%$5.78TYRA+0.50%$32.04AUPH-2.08%$14.57
Snapshot
Index-P/E-EPS (ttm)-Insider Own36.33%Shs Outstand54.78MPerf Week0.30%
Market Cap1.48BForward P/E-EPS next Y-3.70Insider Trans11.30%Shs Float35.26MPerf Month-6.26%
Enterprise Value1.16BPEG0.21EPS next Q-Inst Own-Short Float26.42%Perf Quarter25.58%
Income-141.92MP/S0.00EPS this Y-Inst Trans-Short Ratio13.67Perf Half Y60.26%
Sales0.00P/B3.20EPS next Y-6.17%ROA-28.42%Short Interest9.32MPerf YTD61.02%
Book/sh-P/C-EPS next 5Y-ROE-35.89%52W High29.43 -12.55%Perf Year133.62%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-33.77%52W Low9.09 183.18%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility5.98% 5.16%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-122.40%Oper. Margin0.00%ATR (14)1.47Perf 10Y-
Dividend Ex-Date-Quick Ratio13.85Sales Y/Y TTM-Profit Margin0.00%RSI (14)51.55Recom2.29
Dividend Gr. 3/5Y-Current Ratio13.85EPS Q/Q-36.76%SMA20-3.02%Beta1.11Target Price32.33
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA508.54%Rel Volume1.00Prev Close27.10
Employees103LT Debt/Eq0.00EarningsAug 11SMA20036.03%Avg Volume687.32KPrice25.74
IPO DateSep 13, 2024Option/ShortYes / YesEPS/Sales Surpr.-43.23% -Net Debt/EBITDA2.05Volume689,859Change-5.02%
Analyst Ratings
DateActionAnalystRatingTarget
May-12-26ReiteratedMorgan StanleyOverweight$35 → $37
May-12-26ReiteratedGoldman SachsNeutral$14 → $18
May-11-26InitiatedGuggenheimBuy$42
Feb-11-26ReiteratedGoldman Sachs$14
Jan-08-26InitiatedBTIGBuy$28
Dec-17-25InitiatedMizuhoNeutral$18
Aug-22-25ReiteratedHC Wainwright & Co.Buy$40
May-23-25UpgradeWells FargoUnderweight → Equal Weight$8.00
Mar-27-25ReiteratedStifel Nicolaus$47 → $48
Oct-08-24InitiatedMorgan StanleyOverweight$35
Latest News
Company

Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
Total Revenue
0000
Cost of Goods Sold Incl. D&A
0000
Gross Profit
0000
Selling, General and Administrative Excl. Other311996
Research and Development125643131
Other Operating Expense0-101
Operating Income-156-82-40-38
Interest Expense
0000
Unusual Expense
————
Non-Operating Income (Expense)1815-120
Net Income Before Taxes-138-68-52-38
Income Taxes
0000
Consolidated Net Income-138-68-52-38
Net Income From Continuing Operations-138-68-52-38
Net Income-138-68-52-38
EPS (Recurring)-2.52-1.25-1.00-0.73
EPS (Basic, Before Extraordinaries)-2.52-1.25-1.00-0.73
EPS (Diluted)-2.52-1.25-1.00-0.73
EBITDA-138-68-52-38
Other After Tax Adjustments
————
Stock Option Compensation Expense
————
Price To Earnings Ratio
————
Price To Sales Ratio
————
Gross Margin
————
Operating Margin
————
Net Margin
————
Shares Outstanding55545252
Market Capitalization926941——
Operating Lease Expense
————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$33.65$26.60$19.55$12.51$5.46● Close Price0.00M1.20M2.40M3.60M4.80MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Mazumdar ClaireChief Executive OfficerJul 10 '26Option Exercise3.7910,00037,898372,152Jul 14
Mazumdar ClaireChief Executive OfficerJul 10 '26Sale28.4210,000284,198362,152Jul 14
Cohlhepp RyanPresident and COOJul 09 '26Sale29.0053615,544181,641Jul 10
Hyep IvanChief Financial OfficerJul 08 '26Sale28.8528,000807,672129,855Jul 10
Hyep IvanChief Financial OfficerJul 08 '26Option Exercise3.7925,00094,745157,855Jul 10
Cohlhepp RyanPresident and COOJul 08 '26Option Exercise3.7918,75071,059210,391Jul 10
Cohlhepp RyanPresident and COOJul 08 '26Sale28.9828,214817,586182,177Jul 10
Hyep IvanChief Financial OfficerMay 21 '26Sale20.429,200187,883145,355May 26
Hyep IvanChief Financial OfficerMay 21 '26Option Exercise3.799,20034,866154,555May 26
Mazumdar ClaireChief Executive OfficerMay 18 '26Option Exercise3.7915,00056,847377,152May 20
Mazumdar ClaireChief Executive OfficerMay 18 '26Sale20.0415,000300,579362,152May 20
Cohlhepp RyanPresident and COOMay 15 '26Option Exercise3.798,00030,318204,141May 18
Cohlhepp RyanPresident and COOMay 15 '26Sale20.2912,500253,649191,641May 18
Raben DavidChief Medical OfficerApr 27 '26Option Exercise3.795,50020,84460,786Apr 28
Raben DavidChief Medical OfficerApr 27 '26Sale22.885,500125,83055,286Apr 28
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.